Finance

Lists
Why is CCEL down 2,64%?
Dive Deeper
CCEL:NYSEAMERICAN
Cryo-Cell International Inc
US$4,05
-2,64%
(-0,11) 1D
29 āš.āš., 16 āŧ‚āšĄāš‡ 0 āš™āšēāš—āšĩ 00 āš§āšīāš™āšēāš—āšĩ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CCEL...
Open
US$4,05
High
US$4,05
Low
US$4,05
Mkt. cap
32,65 āšĨāŧ‰āšēāš™
Avg. vol.
15,86Â āšžāšąāš™
Volume
545,00
52-wk high
US$4,90
52-wk low
US$2,72
EPS
US$-0,31
Beta
0,06
Shares outstanding
8,06 āšĨāŧ‰āšēāš™
No. of employees
74
Open
US$4,05
High
US$4,05
Low
US$4,05
Mkt. cap
32,65 āšĨāŧ‰āšēāš™
Avg. vol.
15,86Â āšžāšąāš™
Volume
545,00
52-wk high
US$4,90
52-wk low
US$2,72
EPS
US$-0,31
Beta
0,06
Shares outstanding
8,06 āšĨāŧ‰āšēāš™
No. of employees
74
Profile
Cryo-Cell International, Inc. is a cord blood bank. It was founded by Dan Richard in 1989. Cryo-Cell International is the first private cord blood bank to separate and store stem cells. Cryo-Cell is headquartered outside of Tampa, in Oldsmar, Florida. In January 1997, the Company's stock began trading on the NASDAQ Small Cap market under symbol CCEL. Wikipedia
About Cryo-Cell International Inc
CEOMark L. Portnoy | David I. Portnoy
Employees74
Founded1989
HeadquartersOldsmar, āšŸāšĨāŧāšĢāšīāš”āšē, āšŠāš°āšŦāš°āšĨāšąāš”
SectorHealth care provider
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
āšŠ.āšŦ. 2025
āšž.āšˆ. 2025
āš.āšž. 2026
āšž.āšž. 2026
Revenue
7,83 āšĨāŧ‰āšēāš™
7,84 āšĨāŧ‰āšēāš™
7,68 āšĨāŧ‰āšēāš™
7,78 āšĨāŧ‰āšēāš™
Cost of goods sold
1,80 āšĨāŧ‰āšēāš™
6,09 āšĨāŧ‰āšēāš™
1,66 āšĨāŧ‰āšēāš™
1,68 āšĨāŧ‰āšēāš™
Cost of revenue
1,80 āšĨāŧ‰āšēāš™
6,09 āšĨāŧ‰āšēāš™
1,66 āšĨāŧ‰āšēāš™
1,68 āšĨāŧ‰āšēāš™
Research and development expenses
61,62Â āšžāšąāš™
84,78Â āšžāšąāš™
65,76Â āšžāšąāš™
99,78Â āšžāšąāš™
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,88 āšĨāŧ‰āšēāš™
5,45 āšĨāŧ‰āšēāš™
5,01 āšĨāŧ‰āšēāš™
4,62 āšĨāŧ‰āšēāš™
Operating expense
4,12 āšĨāŧ‰āšēāš™
5,72 āšĨāŧ‰āšēāš™
5,26 āšĨāŧ‰āšēāš™
4,90 āšĨāŧ‰āšēāš™
Total operating expenses
5,92 āšĨāŧ‰āšēāš™
11,81 āšĨāŧ‰āšēāš™
6,92 āšĨāŧ‰āšēāš™
6,58 āšĨāŧ‰āšēāš™
Operating income
1,90 āšĨāŧ‰āšēāš™
-3,97 āšĨāŧ‰āšēāš™
765,13Â āšžāšąāš™
1,20 āšĨāŧ‰āšēāš™
Other non operating income
17,56Â āšžāšąāš™
18,41Â āšžāšąāš™
8,34Â āšžāšąāš™
338,00
EBT including unusual items
1,19 āšĨāŧ‰āšēāš™
-4,63 āšĨāŧ‰āšēāš™
70,31Â āšžāšąāš™
827,78Â āšžāšąāš™
EBT excluding unusual items
1,38 āšĨāŧ‰āšēāš™
-4,43 āšĨāŧ‰āšēāš™
310,77Â āšžāšąāš™
755,76Â āšžāšąāš™
Income tax expense
436,59Â āšžāšąāš™
-814,54Â āšžāšąāš™
23,20Â āšžāšąāš™
273,20Â āšžāšąāš™
Effective tax rate
36,81%
17,59%
33,00%
33,00%
Other operating expenses
-
-
-
-
Net income
749,41Â āšžāšąāš™
-3,82 āšĨāŧ‰āšēāš™
47,11Â āšžāšąāš™
554,59Â āšžāšąāš™
Net profit margin
9,58%
-48,67%
0,61%
7,13%
Earnings per share
0,10
-0,47
0,02
0,07
Interest and investment income
-
-
-
-
Interest expense
-538,22Â āšžāšąāš™
-481,95Â āšžāšąāš™
-462,71Â āšžāšąāš™
-441,92Â āšžāšąāš™
Net interest expenses
-538,22Â āšžāšąāš™
-481,95Â āšžāšąāš™
-462,71Â āšžāšąāš™
-441,92Â āšžāšąāš™
Depreciation and amortization charges
185,69Â āšžāšąāš™
183,83Â āšžāšąāš™
183,89Â āšžāšąāš™
184,33Â āšžāšąāš™
EBITDA
2,14 āšĨāŧ‰āšēāš™
-3,72 āšĨāŧ‰āšēāš™
1,01 āšĨāŧ‰āšēāš™
1,44 āšĨāŧ‰āšēāš™
Gain or loss from assets sale
633,00
-
-
-
AI content may include mistakes. Learn more
āŧāš­āšąāššāš‚āš­āš‡ Google